β(2)-microglobulin Normalization Within 6 months of Ibrutinib-based Treatment is Associated with Superior PFS in CLL

High pre-treatment β(2)-microglobulin (B2M) level is associated with inferior survival outcomes. However, the prognostic and predictive significance of changes in B2M during treatment have not been reported. We analyzed 83 patients treated with ibrutinib-based regimens (66 relapsed/refractory) and 1...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer
Main Authors: Thompson, Philip A., O’Brien, Susan M., Xiao, Lianchun, Wang, Xuemei, Burger, Jan A., Jain, Nitin, Ferrajoli, Alessandra, Estrov, Zeev, Keating, Michael J., Wierda, William G.
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4813299/
https://ncbi.nlm.nih.gov/pubmed/26588193
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29794
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares